Following recent media coverage, we’ve seen a significant increase in patient enquiries about Mounjaro (tirzepatide) and other weight management injections.
These medications are currently being rolled out in phases under NHS England’s national programme. Strict eligibility criteria apply, and only certain patients can be considered during each phase.
Who Is Eligible?Eligibility depends on your BMI, ethnic background, and the presence of certain health conditions (known as comorbidities). The rollout is happening in three cohorts:
Cohort 1 – From 23 June 2025• BMI of 40 or higher, or 37.5 or higher if you are from a South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean background
• Plus at least 4 of the following conditions:
o High blood pressure (on treatment)
o High cholesterol (on statins or similar medication)
o Obstructive sleep apnoea
o Cardiovascular disease
o Type 2 diabetes
Our practice has already reviewed records and contacted eligible patients in Cohort 1 directly. If you have not been contacted, you are not currently eligible under this phase. Cohort 2 – From June 2026 (exact date to be confirmed)• BMI of 35 or higher, or 32.5 or higher if from an eligible ethnic background (as above)
• Plus at least 4 of the same listed conditions
Cohort 3 – From April 2027 (exact date to be confirmed)• BMI of 40 or higher, or 37.5 or higher if from an eligible ethnic background
• Plus at least 3 of the same listed conditions
Please Note• We are unable to prescribe Mounjaro or similar medications for weight loss outside these NHS guidelines
• If you are not eligible, we encourage all patients to continue engaging with existing weight management support, including the NHS 12 week weight loss plan – https://www.nhs.uk/better-health/lose-weight/
For more information, visit NHS England’s official guidance.
We appreciate your understanding and cooperation.